In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EyeTect: Starting Over with OMT for Neuro Intensive Care

Executive Summary

For its first three years, EyeTect, developers of an innovative technology using ocular microtremors to monitor brain function, was the very model of efficient device development. With less than $1 million raised, the company developed a working device, funded several important clinical studies, and even got FDA clearance. But when an anticipated marketing agreement with a well-established competitor fell through, the company all but shut down. Now EyeTect is starting again, with a new managment team and a new target application.

Related Content

Rethinking Alzheimer's: Mapping Out an Approval Process


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts